Generic Name and Formulations:
Choriogonadotropin alfa (r-hCG) 250mcg/0.5mL; liq for SC inj.
EMD Serono, Inc.
Indications for OVIDREL:
Induction of final follicular maturation and early luteinization in infertile women as part of an Assisted Reproductive Technology (ART) program. Ovulation induction where infertility is not due to ovarian failure.
250mg SC one day after last dose of follicle-stimulating agent, if adequate follicular development is evident, and only if there is no evidence of excessive ovarian response (e.g., significant ovarian enlargement, excessive estradiol production, multiple follicular development seen on ultrasound).
Ovarian enlargement and excessive follicular recruitment while undergoing menotropin therapy. Primary ovarian failure. Uncontrolled thyroid or adrenal dysfunction. Uncontrolled intracranial lesion (eg, pituitary tumor). Abnormal genital bleeding. Ovarian cyst or enlargement. Sex hormone-dependent tumors of reproductive system. Pregnancy (Cat.X).
Do complete gynecological and endocrinological exam first. Cardiac or renal disease. Epilepsy. Migraine. Asthma. Nursing mothers.
Ovarian hyperstimulation syndrome (discontinue if occurs) or enlargement, ascites, pleural effusion, ovarian cyst rupture, abdominal pain, multiple births, arterial thromboembolism, headache, irritability, restlessness, depression, fatigue, edema, local reactions.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL